Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

Background: Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evalu...

Full description

Bibliographic Details
Main Authors: Facchini, Gaetano, Caffo, Orazio, Ortega, Cinzia, D'Aniello, Carmine, Di Napoli, Marilena, Cecere, Sabrina C., Della Pepa, Chiara, Crispo, Anna, Maines, Francesca, Ruatta, Fiorella, Iovane, Gelsomina, Pisconti, Salvatore, Montella, Maurizio, Berretta, Massimiliano, Pignata, Sandro, Cavaliere, Carla
Format: Online
Language:English
Published: Frontiers Media S.A. 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870277/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870277/

Similar Items